tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate

tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate Property

Boiling point:

320.7±27.0 °C(Predicted)

Density 

1.118±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

pka

14.85±0.10(Predicted)

Appearance

White to off-white Solid

optical activity

Consistent with structure

InChI

InChI=1S/C10H19NO4/c1-10(2,3)15-9(13)11-4-5-14-7-8(11)6-12/h8,12H,4-7H2,1-3H3/t8-/m1/s1

InChIKey

AIQSXVGBMCJQAG-MRVPVSSYSA-N

SMILES

N1(C(OC(C)(C)C)=O)CCOC[C@H]1CO

Safety

HS Code 

2934999090

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H332Harmful if inhaled

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

tert-Butyl (3R)-3-(hydroxymethyl)morpholine-4-carboxylate Chemical Properties,Usage,Production

Uses

An intermediate of BMS-599626, a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases.

Synthesis

General procedure: [R-(4-benzylmorpholin-3-yl)]-methanol hydrochloride (1 eq.), aqueous K3PO4 (4.6 eq.) and EtOAc were mixed and stirred until two clarified phases were formed. The EtOAc layer was separated and the aqueous layer was extracted with fresh EtOAc. The EtOAc layers were combined and added to a flask containing 20 wt% Pd(OH)2/C (50% aqueous wet, 0.10 eq. based on input weight). Di-tert-butyl dicarbonate (1.2 eq.) was then added. The mixture was hydrogenated at 15 psi hydrogen pressure for 4 hours. Upon completion of the reaction (monitored by HPLC), the mixture was filtered through diatomaceous earth and the solvent was replaced with cyclohexane. By crystallization from cyclohexane (7-10 v/v), tert-butyl (R)-3-(hydroxymethyl)morpholine-4-carboxylate was obtained as a white solid (82% yield). The product characterization data were as follows: 1H NMR (CDCl3) δ 1.45 (s, 9H), 3.17 (m, 1H), 3.47 (dt, 1H, J = 3.1, 11.4 Hz), 3.56 (dd, 1H, J = 3.5, 11.9 Hz), 3.7-4.0 (m, 6H); 13C NMR (CDCl3) δ 28.21, 40.01, 52.09, 59.59, 65.97, 66.49, 80.23, 155.30; MS: 218 (M + H)+; Calculated Elemental Analysis (C10H19NO4): C, 55.28; H, 8.81; N, 6.44; Measured Values: C, 55.45; H, 8.87; N, 6.34; Pd <5 ppm HPLC retention time: 5.28 min (YMC Pack ODS-A, 3 μm, 4.6×50 mm column, 10 min gradient, 2.5 mL/min); 100% ee [Chiral HPLC retention time: 13.6 min (Chiralcel OD-RH, 5 μm, 4.6×150 mm column, 20 min isocratic, 1 mL/ min)]. min)].

References

[1] Patent: WO2005/58245, 2005, A2. Location in patent: Page/Page column 31-32
[2] Patent: WO2005/58245, 2005, A2. Location in patent: Page/Page column 31-32